microRNA-1246 is an exosomal biomarker for aggressive prostate cancer

Divya Bhagirath, Thao Ly Yang, Nathan Bucay, Kirandeep Sekhon, Shahana Majid, Varahram Shahryari, Rajvir Dahiya, Yuichiro Tanaka, Sharanjot Saini

Research output: Contribution to journalArticle

Abstract

Because of high heterogeneity, molecular characterization of prostate cancer based on biopsy sampling is often challenging. Hence, a minimally invasive method to determine the molecular imprints of a patient's tumor for risk stratification would be advantageous. In this study, we employ a novel, digital amplification-free quantification method using the nCounter technology (NanoString Technologies) to profile exosomal serum miRNAs (ex-miRNA) from aggressive prostate cancer cases, benign prostatic hyperplasia, and disease-free controls. We identified several dysregulated miRNAs, one of which was the tumor suppressor miR-1246. miR-1246 was downregulated in prostate cancer clinical tissues and cell lines and was selectively released into exosomes. Overexpression of miR-1246 in a prostate cancer cell line significantly inhibited xenograft tumor growth in vivo and increased apoptosis and decreased proliferation, invasiveness, and migration in vitro. miR-1246 inhibited N-cadherin and vimentin activities, thereby inhibiting epithelial–mesenchymal transition. Ex-miR-1246 expression correlated with increasing pathologic grade, positive metastasis, and poor prognosis. Our analyses suggest ex-miR-1246 as a promising prostate cancer biomarker with diagnostic potential that can predict disease aggressiveness. Significance: Dysregulation of exosomal miRNAs in aggressive prostate cancer leads to alteration of key signaling pathways associated with metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)1833-1844
Number of pages12
JournalCancer Research
Volume78
Issue number7
DOIs
StatePublished - Apr 1 2018
Externally publishedYes

Fingerprint

MicroRNAs
Prostatic Neoplasms
Biomarkers
Prostatic Diseases
Exosomes
Technology
Cell Line
Neoplasms
Prostatic Hyperplasia
Vimentin
Cadherins
Tumor Biomarkers
Heterografts
Down-Regulation
Apoptosis
Neoplasm Metastasis
Biopsy
Growth
Serum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bhagirath, D., Yang, T. L., Bucay, N., Sekhon, K., Majid, S., Shahryari, V., ... Saini, S. (2018). microRNA-1246 is an exosomal biomarker for aggressive prostate cancer. Cancer Research, 78(7), 1833-1844. https://doi.org/10.1158/0008-5472.CAN-17-2069

microRNA-1246 is an exosomal biomarker for aggressive prostate cancer. / Bhagirath, Divya; Yang, Thao Ly; Bucay, Nathan; Sekhon, Kirandeep; Majid, Shahana; Shahryari, Varahram; Dahiya, Rajvir; Tanaka, Yuichiro; Saini, Sharanjot.

In: Cancer Research, Vol. 78, No. 7, 01.04.2018, p. 1833-1844.

Research output: Contribution to journalArticle

Bhagirath, D, Yang, TL, Bucay, N, Sekhon, K, Majid, S, Shahryari, V, Dahiya, R, Tanaka, Y & Saini, S 2018, 'microRNA-1246 is an exosomal biomarker for aggressive prostate cancer', Cancer Research, vol. 78, no. 7, pp. 1833-1844. https://doi.org/10.1158/0008-5472.CAN-17-2069
Bhagirath D, Yang TL, Bucay N, Sekhon K, Majid S, Shahryari V et al. microRNA-1246 is an exosomal biomarker for aggressive prostate cancer. Cancer Research. 2018 Apr 1;78(7):1833-1844. https://doi.org/10.1158/0008-5472.CAN-17-2069
Bhagirath, Divya ; Yang, Thao Ly ; Bucay, Nathan ; Sekhon, Kirandeep ; Majid, Shahana ; Shahryari, Varahram ; Dahiya, Rajvir ; Tanaka, Yuichiro ; Saini, Sharanjot. / microRNA-1246 is an exosomal biomarker for aggressive prostate cancer. In: Cancer Research. 2018 ; Vol. 78, No. 7. pp. 1833-1844.
@article{4528f06877744c5496340a1186a0b632,
title = "microRNA-1246 is an exosomal biomarker for aggressive prostate cancer",
abstract = "Because of high heterogeneity, molecular characterization of prostate cancer based on biopsy sampling is often challenging. Hence, a minimally invasive method to determine the molecular imprints of a patient's tumor for risk stratification would be advantageous. In this study, we employ a novel, digital amplification-free quantification method using the nCounter technology (NanoString Technologies) to profile exosomal serum miRNAs (ex-miRNA) from aggressive prostate cancer cases, benign prostatic hyperplasia, and disease-free controls. We identified several dysregulated miRNAs, one of which was the tumor suppressor miR-1246. miR-1246 was downregulated in prostate cancer clinical tissues and cell lines and was selectively released into exosomes. Overexpression of miR-1246 in a prostate cancer cell line significantly inhibited xenograft tumor growth in vivo and increased apoptosis and decreased proliferation, invasiveness, and migration in vitro. miR-1246 inhibited N-cadherin and vimentin activities, thereby inhibiting epithelial–mesenchymal transition. Ex-miR-1246 expression correlated with increasing pathologic grade, positive metastasis, and poor prognosis. Our analyses suggest ex-miR-1246 as a promising prostate cancer biomarker with diagnostic potential that can predict disease aggressiveness. Significance: Dysregulation of exosomal miRNAs in aggressive prostate cancer leads to alteration of key signaling pathways associated with metastatic prostate cancer.",
author = "Divya Bhagirath and Yang, {Thao Ly} and Nathan Bucay and Kirandeep Sekhon and Shahana Majid and Varahram Shahryari and Rajvir Dahiya and Yuichiro Tanaka and Sharanjot Saini",
year = "2018",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-17-2069",
language = "English (US)",
volume = "78",
pages = "1833--1844",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - microRNA-1246 is an exosomal biomarker for aggressive prostate cancer

AU - Bhagirath, Divya

AU - Yang, Thao Ly

AU - Bucay, Nathan

AU - Sekhon, Kirandeep

AU - Majid, Shahana

AU - Shahryari, Varahram

AU - Dahiya, Rajvir

AU - Tanaka, Yuichiro

AU - Saini, Sharanjot

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Because of high heterogeneity, molecular characterization of prostate cancer based on biopsy sampling is often challenging. Hence, a minimally invasive method to determine the molecular imprints of a patient's tumor for risk stratification would be advantageous. In this study, we employ a novel, digital amplification-free quantification method using the nCounter technology (NanoString Technologies) to profile exosomal serum miRNAs (ex-miRNA) from aggressive prostate cancer cases, benign prostatic hyperplasia, and disease-free controls. We identified several dysregulated miRNAs, one of which was the tumor suppressor miR-1246. miR-1246 was downregulated in prostate cancer clinical tissues and cell lines and was selectively released into exosomes. Overexpression of miR-1246 in a prostate cancer cell line significantly inhibited xenograft tumor growth in vivo and increased apoptosis and decreased proliferation, invasiveness, and migration in vitro. miR-1246 inhibited N-cadherin and vimentin activities, thereby inhibiting epithelial–mesenchymal transition. Ex-miR-1246 expression correlated with increasing pathologic grade, positive metastasis, and poor prognosis. Our analyses suggest ex-miR-1246 as a promising prostate cancer biomarker with diagnostic potential that can predict disease aggressiveness. Significance: Dysregulation of exosomal miRNAs in aggressive prostate cancer leads to alteration of key signaling pathways associated with metastatic prostate cancer.

AB - Because of high heterogeneity, molecular characterization of prostate cancer based on biopsy sampling is often challenging. Hence, a minimally invasive method to determine the molecular imprints of a patient's tumor for risk stratification would be advantageous. In this study, we employ a novel, digital amplification-free quantification method using the nCounter technology (NanoString Technologies) to profile exosomal serum miRNAs (ex-miRNA) from aggressive prostate cancer cases, benign prostatic hyperplasia, and disease-free controls. We identified several dysregulated miRNAs, one of which was the tumor suppressor miR-1246. miR-1246 was downregulated in prostate cancer clinical tissues and cell lines and was selectively released into exosomes. Overexpression of miR-1246 in a prostate cancer cell line significantly inhibited xenograft tumor growth in vivo and increased apoptosis and decreased proliferation, invasiveness, and migration in vitro. miR-1246 inhibited N-cadherin and vimentin activities, thereby inhibiting epithelial–mesenchymal transition. Ex-miR-1246 expression correlated with increasing pathologic grade, positive metastasis, and poor prognosis. Our analyses suggest ex-miR-1246 as a promising prostate cancer biomarker with diagnostic potential that can predict disease aggressiveness. Significance: Dysregulation of exosomal miRNAs in aggressive prostate cancer leads to alteration of key signaling pathways associated with metastatic prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85047858961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047858961&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-2069

DO - 10.1158/0008-5472.CAN-17-2069

M3 - Article

C2 - 29437039

AN - SCOPUS:85047858961

VL - 78

SP - 1833

EP - 1844

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -